Aquestive Therapeutics, Inc.
NASDAQAQST utilization hits 100%, highest level in 52 weeks, as borrow availability plummets to 8.5% of short interest.
Aquestive Therapeutics enters the week with short sellers pressing harder against a stock that just lost 10% in five sessions — and the borrow market is nearly as tight as it gets. The most striking development is the…
Aquestive Therapeutics heads into today's earnings print with options traders at their most defensive in a year, even as short sellers show early signs of pulling back. The options market is sending the loudest…
Snapshot as of 28 Sept 2026
Aquestive Therapeutics enters the final week of June carrying two contradictory signals: the stock is up 7.6% over the past month — riding a 43.77% spike after the FDA waived an advisory committee meeting for its…
Aquestive Therapeutics reports Q1 results today with a notable insider selling cluster dominating the pre-earnings backdrop. The insider signal is the sharpest data point heading in. Five executives — including the…
Aquestive Therapeutics heads into its Q1 earnings release tomorrow with the entire C-suite having sold shares within the past week — a cluster of insider exits that frames everything else on the tape. The insider…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AQST — free to start on ORTEX.
Sign up for free →Open AQST on ORTEX